![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Djoke Hendriks, Yuan He, Iris Koopmans, Valerie R. Wiersma, Robert J. van Ginkel, Douwe F. Samplonius, Wijnand Helfrich & Edwin Bremer. (2016) Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. OncoImmunology 5:8.
Read now
Read now
Mala K Talekar, Joshua E Allen, David T Dicker & Wafik S El-Deiry. (2015) ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle 14:15, pages 2422-2428.
Read now
Read now
Valerie R Wiersma, Marco de Bruyn, Ce Shi, Marloes JM Gooden, Maartje CA Wouters, Douwe F Samplonius, Djoke Hendriks, Hans W Nijman, Yunwei Wei, Jin Zhou, Wijnand Helfrich & Edwin Bremer. (2015) C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. mAbs 7:2, pages 321-330.
Read now
Read now
Namrata Iyer, Sandhya A. Marathe, Debalina Chaudhuri, Preeti Garai & Dipshikha Chakravortty. (2012) Immunomodulation using agonists and antagonists: potential clinical applications. Expert Opinion on Investigational Drugs 21:1, pages 67-81.
Read now
Read now
Articles from other publishers (37)
Yue Zhang, Gui Zhao, Yi‐Fang Chen, Shi‐Kun Zhou, Yue Wang, Yi‐Qun Sun, Song Shen, Cong‐Fei Xu & Jun Wang. (2023) Engineering nano‐clustered multivalent agonists to cross‐link TNF receptors for cancer therapy. Aggregate.
Crossref
Crossref
Yang Wang, Igor Baars, Ferenc Fördös & Björn Högberg. (2021) Clustering of Death Receptor for Apoptosis Using Nanoscale Patterns of Peptides. ACS Nano 15:6, pages 9614-9626.
Crossref
Crossref
Navgeet Kaur, Anju Goyal & Rakesh K. Sindhu. (2020) Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anti-Cancer Agents in Medicinal Chemistry 20:16, pages 1895-1907.
Crossref
Crossref
Md. Ataur Rahman, Subbroto Kumar Saha, Md Saidur Rahman, Md Jamal Uddin, Md. Sahab Uddin, Myung-Geol Pang, Hyewhon Rhim & Ssang-Goo Cho. (2020) Molecular Insights Into Therapeutic Potential of Autophagy Modulation by Natural Products for Cancer Stem Cells. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Yoshimi Endo Greer, Samuel F. Gilbert, Brunilde Gril, Rajesh Narwal, Danielle L. Peacock Brooks, David A. Tice, Patricia S. Steeg & Stanley Lipkowitz. (2019) MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Research 21:1.
Crossref
Crossref
Yu Zhang, Yujie Zhang, Qin Guo, Zhongyuan Guo, Xinli Chen, Lisha Liu, Chao Li, Qinjun Chen, Xi He, Yifei Lu, Tao Sun, Yongzhuo Huang & Chen Jiang. (2019) Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein. ACS Applied Materials & Interfaces 11:26, pages 23018-23025.
Crossref
Crossref
Jürgen Scheller, Erika Engelowski, Jens M. Moll & Doreen M. Floss. (2019) Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Trends in Immunology 40:3, pages 258-272.
Crossref
Crossref
Minwoo Kih, Eun Jung Lee, Na Kyeong Lee, Yoon Kyoung Kim, Kyung Eun Lee, Cherlhyun Jeong, Yoosoo Yang, Dong-Hwee Kim & In-San Kim. (2018) Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages. Biomaterials 180, pages 67-77.
Crossref
Crossref
Eun-Sil Sung & Yong-Sung Kim. 2018. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
5592
5600
.
D. Hendriks, G. Choi, M. de Bruyn, V.R. Wiersma & E. Bremer. 2017.
289
383
.
R Polanski, J Vincent, U M Polanska, T Petreus & E K Y Tang. (2015) Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines. Cell Death & Disease 6:10, pages e1893-e1893.
Crossref
Crossref
Fatih M. Uckun, Dorothea E. Myers, Hong Ma, Rebecca Rose & Sanjive Qazi. (2015) Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand×Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice. EBioMedicine 2:4, pages 306-316.
Crossref
Crossref
Fatih M. Uckun, Dorothea E. Myers, Sanjive Qazi, Zahide Ozer, Rebecca Rose, Osmond J. D’Cruz & Hong Ma. (2015) Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia. Journal of Clinical Investigation 125:3, pages 1006-1018.
Crossref
Crossref
Yu. N. Lezhnin, Yu. E. Kravchenko, E. I. Frolova, P. M. Chumakov & S. P. Chumakov. (2015) Oncotoxic proteins in cancer therapy: Mechanisms of action. Molecular Biology 49:2, pages 231-243.
Crossref
Crossref
Jieqing Zhu, Longfei Chen, Juan Shi, Shilian Liu, Yanxin Liu & Dexian Zheng. (2014) TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis. Immunology 141:2, pages 211-221.
Crossref
Crossref
Sunil Sharma, Elisabeth G. de Vries, Jeffrey R. Infante, Corina N. Oldenhuis, Jourik A. Gietema, Lin Yang, Sanela Bilic, Katie Parker, Michael Goldbrunner, Jeffrey W. Scott & Howard A. BurrisIIIIII. (2013) Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs 32:1, pages 135-144.
Crossref
Crossref
Valerie R. Wiersma, Yuan He, Douwe F. Samplonius, Robert J. van Ginkel, Jurjen Gerssen, Paul Eggleton, Jin Zhou, Edwin Bremer & Wijnand Helfrich. (2014) A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. British Journal of Haematology 164:2, pages 304-307.
Crossref
Crossref
Evangelos Pazarentzos & Nicholas D. Mazarakis. 2014. Anticancer Genes. Anticancer Genes
255
280
.
Eftychia Oikonomou & Alexander Pintzas. (2013) The TRAIL of oncogenes to apoptosis. BioFactors 39:4, pages 343-354.
Crossref
Crossref
Edwin Bremer. (2013) Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy. ISRN Oncology 2013, pages 1-25.
Crossref
Crossref
Michael Croft, Chris A. Benedict & Carl F. Ware. (2013) Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery 12:2, pages 147-168.
Crossref
Crossref
Anita C. Bellail & Chunhai Hao. 2013. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
213
243
.
Chunxia Qiao, Meiyun Hu, Leiming Guo, Ming Lv, Zhou Lin, Jing Geng, Xiaoling Lang, Xinying Li, Yan Li, Yuanfang Ma, Jiannan Feng & Beifen Shen. (2012) Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation. BMC Immunology 13:1.
Crossref
Crossref
Farhan Basit, Robin Humphreys & Simone Fulda. (2012) RIP1 Protein-dependent Assembly of a Cytosolic Cell Death Complex Is Required for Inhibitor of Apoptosis (IAP) Inhibitor-mediated Sensitization to Lexatumumab-induced Apoptosis. Journal of Biological Chemistry 287:46, pages 38767-38777.
Crossref
Crossref
Chris A. Benedict & Carl F. Ware. (2012) TRAIL: not just for tumors anymore?. Journal of Experimental Medicine 209:11, pages 1903-1906.
Crossref
Crossref
Eun-Sil Sung, Kyung-Jin Park, Hye-Ji Choi, Chul-Ho Kim & Yong-Sung Kim. (2012) The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Experimental Cell Research 318:13, pages 1564-1576.
Crossref
Crossref
Lun K Tsou, Yao Cheng & Yung-Chi Cheng. (2012) Therapeutic development in targeting protein–protein interactions with synthetic topological mimetics. Current Opinion in Pharmacology 12:4, pages 403-407.
Crossref
Crossref
Jamie D. Bulken-Hoover, Wesley M. Jackson, Youngmi Ji, Jared A. Volger, Rocky S. Tuan & Leon J. Nesti. (2011) Inducible Expression of Neurotrophic Factors by Mesenchymal Progenitor Cells Derived from Traumatically Injured Human Muscle. Molecular Biotechnology 51:2, pages 128-136.
Crossref
Crossref
Andrew M. Scott, Jedd D. Wolchok & Lloyd J. Old. (2012) Antibody therapy of cancer. Nature Reviews Cancer 12:4, pages 278-287.
Crossref
Crossref
João Gonçalves, Helena Soares, Norman L. Eberhardt, Sarah C. R. Lummis, David R. Soto-Pantoja, David D. Roberts, Umadas Maitra, Romit Majumdar, Arunima Biswas, Avik Choudhuri, Umadas Maitra, Jayalakshmi Krishnan, Sangdun Choi, Shaikh M. Atif, Stephen J. McSorley, Michael T. Greenwood, Aisha Qasim Butt, Sinéad M. Miggin, Felipe Francisco Tuon, Enda Shevlin, Sinéad M. Miggin, Austin Della-Franca, Yuyan Chen, Jennifer Anne Byrne, Dimitra Virla, Christos Tsatsanis, Aristides G. Eliopoulos, Maréne Landström, Reshma Sundar, Eun-Sil Sung, Yong-Sung Kim, Adrienn Angyal, Endre Kiss-Toth & Christian Harteneck. 2012. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
1921
1928
.
Vinochani Pillay, Hui K. Gan & Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, pages 518-529.
Crossref
Crossref
Chang-Han Lee, Kyung-Jin Park, Sang Jick Kim, Ohsuk Kwon, Ki Jun Jeong, Ayeung Kim & Yong-Sung Kim. (2011) Generation of Bivalent and Bispecific Kringle Single Domains by Loop Grafting as Potent Agonists against Death Receptors 4 and 5. Journal of Molecular Biology 411:1, pages 201-219.
Crossref
Crossref
Jonathan Hall, Patrick Dennler, Stephanie Haller, Anna Pratsinis, Katharina Säuberli, Harry Towbin, Katja Walther & Janine Woytschak. (2010) Genomics drugs in clinical trials. Nature Reviews Drug Discovery 9:12, pages 988-988.
Crossref
Crossref
Eun-Sil Sung, Aeyung Kim, Joon Seong Park, Junho Chung, Myung-Hee Kwon & Yong-Sung Kim. (2010) Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 15:10, pages 1256-1269.
Crossref
Crossref
Howard C. Masuoka & Frank A. Sinicrope. (2010) Clinical Relevance of Apoptotic Regulatory Proteins in Colorectal Cancers. Current Colorectal Cancer Reports 6:3, pages 111-117.
Crossref
Crossref
Jeffrey Wiezorek, Pamela Holland & Jonathan Graves. (2010) Death Receptor Agonists as a Targeted Therapy for Cancer. Clinical Cancer Research 16:6, pages 1701-1708.
Crossref
Crossref
Stefan Grimm & Mathieu Noteborn. (2010) Anticancer genes: inducers of tumour-specific cell death signalling. Trends in Molecular Medicine 16:2, pages 88-96.
Crossref
Crossref